Notification of Dilution of Voting Rights

RNS Number : 6557G

Hutchison China Meditech Limited

27 November 2020

London: Friday, November 27, 2020: Hutchison China MediTech Limited (" Chi-Med ") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (" CK Hutchison ") shareholding^[1] in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of Chi-Med ("Shares").

Each American Depositary Share ("ADS") represents five Shares. As announced on November 17, 2020, Chi-Med issued a total of 16,666,670 Shares (equivalent to 3,333,334 ADSs) to Canada Pension Plan Investment Board. Chi-Med was notified on November 26 , 2020 that this issuance diluted CK Hutchison's holding^[1] to 45.69 per cent of the total number of voting rights of Chi-Med. The date on which the notification threshold was crossed was November 26, 2020.

^[1] Held through CK Hutchison's indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com .

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President	+852 2121 8200
Annie Cheng, Vice President	+1 (973) 567 3786

Media Enquiries
Americas - Brad Miles, Solebury Trout	+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting	+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick	+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97 83 6894 (Mobile), y zhou@brunswickgroup.com

Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited	+44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRUNVURRUUAUAA